January 25, 2023
NIH Data Management and Sharing Policy. Starting January 25 2023, NIH grant applications leading to the generation of scientific data require submission of a 2-page Data Management and Sharing Plan. The NIH is regularly adding new information and guidance on this new requirement. Here are a few links covering the new NIH Data Management and Sharing Policy.
July 12, 2022
Dr Yvonne Edwards is on the Editorial Board of Briefings in Bioinformatics. Dr Yvonne Edwards served as one of three Associate Editors working with the Editor in Chief for the journal Briefings in Bioinformatics which is ranked #1 in the world out of 57 journals which are in the category of Mathematical and Computational Biology. This journal has a 2021 impact factor of 13.996.
September 23, 2020
A Bioinformatics Post-Doctoral Position is available in the Collaborative Bioinformatics Research Lab.
April 30, 2020
UAB IT Research Computing announcement, see link here, describes Globus Share Technology enabling remote collaboration at UAB School of Medicine. Dr Yvonne Edwards (Director, Collaborative Bioinformatics Research Lab) and Dr Narendra Wajapeyee (Professor, Vice Chair for Research) are featured in the announcement utilizing Globus Share for remote collaboration. UAB IT Research Computing provided modern technology enabling remote data sharing capabilities and collaboration for big data research. Globus Share proved to be an important collaborative tool during the mandatory lockdown of the UAB campus due to the COVID-19 pandemic.
April 2, 2020
New grants awarded with support from the Collaborative Bioinformatics Research Lab. Dr Kim Keeling (Principal Investigator) and Dr Edwards (Co-Principal Investigator) won a grant award for $500,000 direct costs (over 2 years) for Cystic Fibrosis research “Investigating Nonsense-Mediated mRNA Decay (NMD) as a Therapeutic Target”. One of the goals is to examine how CFTR premature termination codon containing mRNAs are targeted for NMD, allowing us to identify specific and safe NMD targets for the development of new treatments for Cystic Fibrosis patients who carry a nonsense mutation. This is a patient subgroup for which no therapies are currently available. The main goal of the research is to determine whether conditions can be achieved to inhibit NMD so as to raise CFTR mRNA levels without causing toxic side effects.
